This is a double-blind, sham-controlled clinical trial assessing the effectiveness of personalized isometric handgrip device therapy. Approximately 230 patients who present with a Systolic Blood Pressure reading of ≤ 149mmHg and who have not taken any antihypertensive medication for more than 30 days will be enrolled.
This study is designed to examine the effectiveness of individualized isometric handgrip device therapy in prehypertension or hypertension patient subjects who are not at target BP and who are naive to anti-hypertensive medication for at least 30 days before screening. The investigational plan examines changes in blood pressure (BP) in up to 230 patient subjects who are randomized to either the "active" (i.e., the Zona Plus device proposed for marketing), or to a "sham" device (which is intentionally calibrated for a "weaker grip").
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
146
Zona Plus 3.0 Individualized Isometric Handgrip Therapy Device
Zona Plus control sham device, with a nominal weaker grip
Saint Louis Heart & Vascular, P.C.
St Louis, Missouri, United States
Carolinas Research Center LLC
Charlotte, North Carolina, United States
Goldsboro Medical Center
Goldsboro, North Carolina, United States
Sante Clinical Research
Kerrville, Texas, United States
Change from Baseline in Systolic Blood Pressure to Day 70 ± 2 Days
Comparative assessment in the change from Baseline in seated cuff Systolic Blood Pressure after ten(10) weeks of treatment between patients treated with the Zona Plus nominal device ("stronger grip") and patients treated with the Placebo control device ("weaker grip"). A reduction in Systolic Blood ≥ 5 Preassure after 10 weeks of treatment is considered to be a better outcome.
Time frame: Change from Baseline to Day 70 ±2 Days
Change from Baseline in Diastolic Blood Pressure to Day 70 ± 2 Days
Comparative assessment of the change from Baseline in seated cuff Diastolic Blood Pressure after 10 weeks of treatment between patients treated with the Zona Plus nominal device ("stronger grip") and patients treated with the Placebo control device ("weaker grip").
Time frame: Change from Baseline to Day 70 ±2 Days
Percentage change from Baseline in Systolic Blood Pressure reduction at Day 70 ± 2 Days
Comparative assessment in the percentage of patients who achieve a clinically significant Systolic Blood Pressure reduction (defined as ≥ 5 mmHg) at Day 70 ± 2 Days.
Time frame: Change from Baseline to Day 70 ± 2 Days
Percentage change from Baseline in Diastolic Blood Pressure reduction at Day 70 ± 2 Days
Comparative assessment in the percentage of patients who achieve a clinically significant Diastolic Blood Pressure reduction (defined as ≥3 mmHg) at Day 70 ± 2 Days.
Time frame: Change from Baseline to Day 70 ± 2 Days
Percentage change from Baseline in Systolic Blood Pressure reduction at Day 160 ± 4 Days
Comparative assessment in change from Baseline in the seated cuff Systolic Blood Pressure after 6 months Day 160 ± 4 of treatment between patients treated with the Zona Plus nominal device and patients treated with the Placebo control device.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Sun Research Institute
San Antonio, Texas, United States
Time frame: Change from Baseline to Day 160 ± 4 Days
Percentage change in Diastolic Blood Pressure reduction at Day 160 ± 4 Days
Comparative assessment in change from Baseline in the seated cuff Diastolic Blood Pressure after 6 months Day 160 ± 4 Days of treatment between patients treated with the Zona Plus nominal device and patients treated with the Placebo control device.
Time frame: Change from Baseline to Day 160 ± 4 Days
Percentage change from Baseline in Systolic Blood Pressure reduction at Day 160 ± 4 Days
Comparative assessment in the percentage of patients who achieve a clinically significant Systolic Blood Pressure reduction (defined as ≥ 5 mmHg) at Day 160 ± 4 Days
Time frame: Change from Baseline to Day 160 ± 4 Days
Percentage change in Diastolic Blood Pressure reduction at Day 160 ± 4 Days
Comparative assessment in the percentage of patients who achieve a clinically significant Diastolic Blood Pressure reduction defined as ≥3 mmHg at Day 160 ± 4 Days
Time frame: Change from Baseline to Day 160 ± 4 Days
Comparison of Heart Rate between Zona Plus nominal device and Placebo controlled device
The Heart Rate (HR) will be recorded and compared between the Zona Plus nominal device and the Placebo control device treatment groups.
Time frame: Change from Baseline to Day 160 ± 4 Days